Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of glepaglutide versus placebo in adults with short bowel syndrome dependent on parenteral support
NL-OMON52468Phase 3Active, not recruiting
- Sponsor
- Zealand Pharma
- Start
- Apr 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Glepaglutide with Placebo (2 arms). Primary endpoint: Reduction in weekly parenteral support volume from baseline to Week 24. Started Apr 2019; status: active, not recruiting.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NL-OMON52468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52468.